Literature DB >> 19609103

Subclinical hyperthyroidism and sport eligibility: an exploratory study on cardiovascular pre-participation screening in subjects treated with levothyroxine for multinodular goiter.

L Di Luigi1, A Parisi, F Quaranta, F Romanelli, E Tranchita, P Sgrò, P Nardi, G Fattorini, R Cavaliere, F Pigozzi, M D'Armiento, A Lenzi.   

Abstract

BACKGROUND: Subclinical hyperthyroidism (sHT) affects cardiovascular (CV) morphology and function; whether such changes can impact on sport eligibility is unclear. AIM: This exploratory study evaluated the CV system and sport eligibility in athletes with levothyroxine-induced sHT, in the setting of mandatory pre-participation screening. SUBJECTS AND METHODS: A full, non-invasive CV screening (history and physical examination, 12-lead ECG, echocardiography, 24-hour Holter ECG, exercise stress test) was performed in two groups of untrained female athletes affected by non-toxic multinodular goiter. One group was taking levothyroxine at mildly suppressive doses (TG) whereas the other was untreated (UG). There was also a group of healthy controls (HC).
RESULTS: In TG the following characteristics were observed: a) a higher resting heart rate (HR; p<0.01 and p<0.05, vs HC and UG respectively), b) a thicker left ventricular posterior wall (p<0.05 vs HC, and p<0.05 vs HC and UG, respectively), c) a higher mean HR during the 24-hour Holter ECG (p<0.01 and p<0.05, vs HC and UG respectively), and d) a lower achieved maximum work load (p<0.05, vs HC). No differences in the prevalence of cardiac arrhythmias among groups were observed. Sport eligibility was granted to all except one subject in the TG.
CONCLUSIONS: Although some alterations were found in athletes with levothyroxine-induced mild sHT, these are probably of limited clinical relevance and they did not contraindicate sport participation in the majority of cases. Future research to address both health risks and the need for specific evaluations (e.g. free thyroxine, TSH, echocardiography) during the preparticipation screening of athletes with sHT is warranted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609103     DOI: 10.1007/BF03345753

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  37 in total

1.  Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation.

Authors:  Barry J Maron; Paul D Thompson; Michael J Ackerman; Gary Balady; Stuart Berger; David Cohen; Robert Dimeff; Pamela S Douglas; David W Glover; Adolph M Hutter; Michael D Krauss; Martin S Maron; Matthew J Mitten; William O Roberts; James C Puffer
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

2.  Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program.

Authors:  Domenico Corrado; Cristina Basso; Andrea Pavei; Pierantonio Michieli; Maurizio Schiavon; Gaetano Thiene
Journal:  JAMA       Date:  2006-10-04       Impact factor: 56.272

3.  Long-term thyrotropin-suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma.

Authors:  M Shargorodsky; S Serov; D Gavish; E Leibovitz; D Harpaz; R Zimlichman
Journal:  Thyroid       Date:  2006-04       Impact factor: 6.568

4.  Subclinical hyperthyroidism as a risk factor for atrial fibrillation.

Authors:  J Auer; P Scheibner; T Mische; W Langsteger; O Eber; B Eber
Journal:  Am Heart J       Date:  2001-11       Impact factor: 4.749

Review 5.  Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship?

Authors:  Henry Völzke; Christian Schwahn; Henri Wallaschofski; Marcus Dörr
Journal:  J Clin Endocrinol Metab       Date:  2007-05-01       Impact factor: 5.958

6.  Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine.

Authors:  B Biondi; S Fazio; C Carella; D Sabatini; G Amato; A Cittadini; A Bellastella; G Lombardi; L Saccà
Journal:  J Clin Endocrinol Metab       Date:  1994-05       Impact factor: 5.958

7.  Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction.

Authors:  Sevim Gullu; Fevzi Altuntas; Irem Dincer; Cetin Erol; Nuri Kamel
Journal:  Eur J Endocrinol       Date:  2004-05       Impact factor: 6.664

8.  Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of beta-blockade.

Authors:  S Fazio; B Biondi; C Carella; D Sabatini; A Cittadini; N Panza; G Lombardi; L Saccà
Journal:  J Clin Endocrinol Metab       Date:  1995-07       Impact factor: 5.958

9.  Prolonged ventricular repolarization measured by corrected QT interval (QTc) in subclinical hyperthyroidism.

Authors:  M Owecki; A Michalak; E Nikisch; J Sowiński
Journal:  Horm Metab Res       Date:  2006-01       Impact factor: 2.936

10.  Prevalence of abnormal electrocardiograms in a large, unselected population undergoing pre-participation cardiovascular screening.

Authors:  Antonio Pelliccia; Franco Culasso; Fernando M Di Paolo; Domenico Accettura; Rocco Cantore; Walter Castagna; Alberto Ciacciarelli; Gioberto Costini; Biagio Cuffari; Enrico Drago; Vittorio Federici; Carlo Gabriele Gribaudo; Giancarlo Iacovelli; Luigi Landolfi; Giuseppe Menichetti; Umberto Olla Atzeni; Attilio Parisi; Angelo R Pizzi; Michele Rosa; Fabio Santelli; Franco Santilio; Alberto Vagnini; Maurizio Casasco; Luigi Di Luigi
Journal:  Eur Heart J       Date:  2007-07-10       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.